University of Leicester
Browse
1465-9921-8-67.pdf (321.58 kB)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma

Download (321.58 kB)
journal contribution
posted on 2016-04-21, 09:49 authored by Ian Douglas Pavord, Ashley Woodcock, Debbie Parker, Leanne Rice, SOLTA study group
Background: Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids, and little is known about the effects of different treatments on airway inflammation. In this double-blind, placebo-controlled, parallel group study, we compared the effects of salmeterol plus fluticasone propionate (FP) (Seretide™; SFC) and FP plus montelukast (FP/M) on sputum inflammatory markers, airway responsiveness, lung function, and symptoms in adult asthmatics. Methods: Sixty-six subjects were randomised to SFC or FP/M for 12 weeks. The primary outcome was changes in neutrophil, eosinophil, macrophage, lymphocyte, and epithelial cell levels in induced sputum. Additional outcomes included the change in other sputum markers of airway inflammation, airway responsiveness, symptom control, and lung function. Results: Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils. Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M. FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC (treatment ratio 1.80; 95% CI 1.09, 2.94). Conclusion: Both treatments led to similar control of eosinophilic airway inflammation, although PEF and symptom control were better with SFC.

History

Citation

Respiratory Research, 2007, 8, 67

Author affiliation

/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Infection, Immunity and Inflammation

Version

  • VoR (Version of Record)

Published in

Respiratory Research

Publisher

BioMed Central

issn

1465-9921

eissn

1465-993X

Acceptance date

2007-09-27

Copyright date

2007

Available date

2016-04-21

Publisher version

http://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-8-67

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC